| Future and upcoming non-neoplastic applications of PET/CT imaging. | |
| | |
MedLine Citation:
|
PMID: 21718331 Owner: NLM Status: In-Data-Review |
Abstract/OtherAbstract:
|
The role of fluoro-2-deoxyglucose (FDG) positron emission tomography (PET) in the diagnosis, staging, and monitoring of neoplastic conditions is well established. The clinical utility of PET/CT has now expanded to the diagnosis of autoimmune, inflammatory, infectious, as well as non-neoplastic conditions, such as the vasculitides, atherosclerosis, and granulomatous conditions, including sarcoidosis and inflammatory bowel disease, in addition to a variety of neurologic disorders. The availability of new PET radiotracers is expected to expand PET/CT applications to a variety of other clinical domains. New radioligands for studying inflammation and neurodegenerative processes are under development. Here, we discuss the evolving potential role of PET imaging for the evaluation and monitoring of miscellaneous conditions, including osteoarthritis, interstitial lung disease, vascular thromboses, and osteoporosis. |
| | |
Authors:
|
Mandana Hashefi; Rodolfo Curiel |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Annals of the New York Academy of Sciences Volume: 1228 ISSN: 1749-6632 ISO Abbreviation: Ann. N. Y. Acad. Sci. Publication Date: 2011 Jun |
Date Detail:
|
Created Date: 2011-07-01 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 7506858 Medline TA: Ann N Y Acad Sci Country: United States |
Other Details:
|
Languages: eng Pagination: 167-74 Citation Subset: IM |
Copyright Information:
|
© 2011 New York Academy of Sciences. |
Affiliation:
|
Division of Rheumatology, George Washington University, Washington, District of Columbia. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: PET/CT imaging in infectious conditions.
Next Document: Lack of effect of ustekinumab in treatment of allergic contact dermatitis.